Mitchell, Aaron P. http://orcid.org/0000-0003-3639-3515
Meza, Akriti Mishra http://orcid.org/0000-0002-3477-5037
Panageas, Katherine S.
Lipitz-Snyderman, Allison
Farooki, Azeez
Morris, Michael J. http://orcid.org/0000-0002-9454-0096
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R03CA259863, P30CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 20 May 2022
Revised: 22 June 2022
Accepted: 27 June 2022
First Online: 7 July 2022
Competing interests
: APM and AS have no potential conflicts of interest to disclose. AMM declares stock ownership in Johnson & Johnson, DNA, and Teladoc Health. KP declares stock ownership in T2 Biosystems, Adicet Bio, Inc., Chinook Therapeutics, Codexis, and Vincerx Pharma. AF declares consulting for Amgen. MM declares consulting and/or advisory arrangements with Bayer, Novartis, Advanced Accelerator Applications, ORIC Pharmaceuticals, Johnson & Johnson, Curium Pharma, Athenex, Exelixis, AstraZeneca, and Amgen, paid travel for Endocyte and Fujifilm, and research funding from Bayer, Sanofi, Endocyte, Progenics, Corcept Therapeutics, Roche/Genentech, and Janssen.